DE3366933D1 - Antithrombin-heparin complex - Google Patents

Antithrombin-heparin complex

Info

Publication number
DE3366933D1
DE3366933D1 DE8383850140T DE3366933T DE3366933D1 DE 3366933 D1 DE3366933 D1 DE 3366933D1 DE 8383850140 T DE8383850140 T DE 8383850140T DE 3366933 T DE3366933 T DE 3366933T DE 3366933 D1 DE3366933 D1 DE 3366933D1
Authority
DE
Germany
Prior art keywords
antithrombin
heparin complex
heparin
complex
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE8383850140T
Other languages
English (en)
Inventor
Desire J Collen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Kabi Pharmacia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia AB filed Critical Kabi Pharmacia AB
Application granted granted Critical
Publication of DE3366933D1 publication Critical patent/DE3366933D1/de
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
DE8383850140T 1982-06-10 1983-05-24 Antithrombin-heparin complex Expired DE3366933D1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8203611 1982-06-10

Publications (1)

Publication Number Publication Date
DE3366933D1 true DE3366933D1 (en) 1986-11-20

Family

ID=20347038

Family Applications (2)

Application Number Title Priority Date Filing Date
DE198383850140T Pending DE98814T1 (de) 1982-06-10 1983-05-24 Antithrombin-heparin komplex.
DE8383850140T Expired DE3366933D1 (en) 1982-06-10 1983-05-24 Antithrombin-heparin complex

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE198383850140T Pending DE98814T1 (de) 1982-06-10 1983-05-24 Antithrombin-heparin komplex.

Country Status (8)

Country Link
US (1) US4623718A (de)
EP (1) EP0098814B1 (de)
JP (1) JPS5925802A (de)
AT (1) ATE22899T1 (de)
CA (1) CA1205011A (de)
DE (2) DE98814T1 (de)
DK (1) DK258283A (de)
NO (1) NO157783C (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3422518A1 (de) * 1984-06-16 1985-12-19 B. Braun Melsungen Ag, 3508 Melsungen Heparin-derivate, verfahren zu ihrer herstellung, diese enthaltende arzneimittel und ihre verwendung bei der behandlung von fettstoffwechselstoerungen
US4859581A (en) * 1986-03-10 1989-08-22 Board Of Regents, The University Of Texas System Endoglycosidase assay
EP0337327A1 (de) * 1988-04-09 1989-10-18 Bioiberica, S.A. Verfahren zur Herstellung von neuen Oligosaccharid-Fragmenten durch kontrollierte chemische Depolymerisation von Heparin
US5252557A (en) * 1988-07-25 1993-10-12 Kiyoshi Kita Administration method of antithrombin
US6491965B1 (en) 1995-11-30 2002-12-10 Hamilton Civic Hospitals Research Development, Inc. Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US7045585B2 (en) 1995-11-30 2006-05-16 Hamilton Civic Hospital Research Development Inc. Methods of coating a device using anti-thrombin heparin
US6562781B1 (en) 1995-11-30 2003-05-13 Hamilton Civic Hospitals Research Development Inc. Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US20040229778A1 (en) * 2003-05-13 2004-11-18 Elmaleh David R. Pharmaceutical compositions of antithrombin III for the treatment of retroviral diseases
US7498130B2 (en) * 2003-05-13 2009-03-03 Massachusetts General Hospital Method of reducing viral load
US20070196347A1 (en) * 2003-08-12 2007-08-23 Chan Anthony K C Methods for preventing neurological events
CN103743837B (zh) * 2013-12-24 2015-01-21 山东泰邦生物制品有限公司 人抗凝血酶ⅲ肝素结合比例检测方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE12779T1 (de) * 1980-09-30 1985-05-15 Bayer Ag Verfahren zur herstellung eines antithrombinheparin-komplexes sowie diesen komplex enthaltende pharmazeutische mischungen.

Also Published As

Publication number Publication date
NO157783C (no) 1988-05-18
EP0098814B1 (de) 1986-10-15
DK258283A (da) 1983-12-11
DK258283D0 (da) 1983-06-07
DE98814T1 (de) 1984-06-20
NO157783B (no) 1988-02-08
US4623718A (en) 1986-11-18
EP0098814A1 (de) 1984-01-18
JPS5925802A (ja) 1984-02-09
CA1205011A (en) 1986-05-27
NO832092L (no) 1983-12-12
ATE22899T1 (de) 1986-11-15

Similar Documents

Publication Publication Date Title
ES8402290A1 (es) Procedimiento para la preparacion de nuevos 6,11-dihidrodibenzo (b,e)-tiepin-11-n-alcohilnorescopin-eteres cuaternarios.
DE3375790D1 (en) Polymer molecular weight reduction process
DE3368303D1 (en) Cellulosic materials made transparent and their application, process for their manufacture and the treating compositions
ATE94395T1 (de) Verwendung von spezifischen monosacchariden zur herstellung eines arzneimittels zur verhinderung von metastasen maligner tumore.
DE3165361D1 (en) Sulfated polysaccharides, process for their preparation and their use as medicines
ES8501414A1 (es) Procedimiento de sintesis organica de oligosacaridos
HU896510D0 (en) Novel anion-exchange polymers, process for preparing them and pharmaceutical compositions containing them
IL69695A0 (en) Compatible polymer blends of imidized acrylic polymer and polyamide and their use in the production of plastics articles
EP0274721A3 (en) Polymers containing amino groups, their manufacture and their use
MY102586A (en) Medicaments for paf acether induced maladies
DE3366933D1 (en) Antithrombin-heparin complex
JPS56152817A (en) Grafted polymer, manufacture thereof and its use
GR3004988T3 (de)
EP0245813A3 (en) Edta-free heparins, heparin fractions and fragments, processes for their preparation and pharmaceutical compositions containing them
JPS5767563A (en) Novel indene derivative, manufacture and medicine
PH17257A (en) Novel pentapeptides,pharmaceutical compositions comprising said pentapeptides and their use
DE3060453D1 (en) Process for the obtention of low molecular weight hydrocarbons from high molecular weight hydrocarbons or from coal
EP0222522A3 (en) Platinum coordination compounds
DE3165337D1 (en) Bicyclooctane compounds, their production, compositions containing them and their pharmaceutical use
EP0029725A3 (en) Polymers containing cyclic ether units joined through 2,6-diyl linkages
IL88136A0 (en) Compounds containing triazole groups,use thereof as fungicides and preparative processes
JPS5718670A (en) Novel benzoazole derivative,manufacture, pharmaceutic medicine containing it and use
IL61897A0 (en) 1,2,3-triazole derivatives,their production and pharmaceutical compositions containing them
JPS55151512A (en) Novel antithrombotic blended medicine
GR81838B (de)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee